INVO Fertility Posts Surprise Q2 Profit, Shares Surge 53%
IVF sits 71% above its 52-week low of $0.9 on elevated volume (27× avg).
Summary
INVO Fertility reported Q2 EPS of $0.35, a massive beat versus the expected -$0.65 loss, driven by a $2.5 million remeasurement gain on its Birmingham clinic acquisition. Revenue grew 17% to $2.18 million, slightly below consensus, but clinic-level Adjusted EBITDA doubled sequentially to $333K. The stock jumped 53% to $1.49 on the news. This follows a string of going-concern warnings and dilutive financing disclosures, so the surprise profit is a sharp reversal. Watch whether the company can sustain profitability without one-time gains.
At the time of this announcement, IVF was trading at $1.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.6M. The 52-week trading range was $0.90 to $84.40. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Benzinga.